Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited.
Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches.
Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.
1. Cancer Immunology and Immunotherapy - p. i 2. Cover - p. i 3. Title Page - p. ii 4. Copyright Page - p. iv 5. Table of Contents - p. iv 6. Dedication - p. v 7. Contributors - p. xiii 8. Preface - p. xvii 9. Acknowledgments - p. xix 10. Chapter One The hallmarks of cancer and immunology - p. 1 11. Chapter Two Innate and adaptive immunity in cancer - p. 19 12. Chapter Three Inflammation and cancer - p. 63 13. Chapter Four Novel immunotherapeutic approaches to cancer: Voltage-gated sodium channel expression in immune cells and tumors - p. 83 14. Chapter Five Immunoediting and cancer priming - p. 111 15. Chapter Six Metabolic reprogramming and immunity in cancer - p. 137 16. Chapter Seven Epigenetic programming of the immune responses in cancer - p. 197 17. Chapter Eight Cellular therapeutics in immuno-oncology - p. 237 18. Chapter Nine T-cell engaging bispecific antibody therapy - p. 267 19. Chapter Ten Role of microbiome in cancer immunotherapy - p. 321 20. Chapter Eleven STING pathway and modulation for cancer immunotherapy - p. 353 21. Chapter Twelve Oncolytic viruses in immunotherapy - p. 375 22. Chapter Thirteen Comparison of therapeutic strategies for immuno-oncology - p. 439 23. Chapter Fourteen Intrinsic and acquired cancer immunotherapy resistance - p. 463 24. Chapter Fifteen Preclinical and clinical toxicity of immuno-oncology therapies and mitigation strategies - p. 499 25. Index - p. 515
Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited.
Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches.
Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.
1. Cancer Immunology and Immunotherapy - p. i 2. Cover - p. i 3. Title Page - p. ii 4. Copyright Page - p. iv 5. Table of Contents - p. iv 6. Dedication - p. v 7. Contributors - p. xiii 8. Preface - p. xvii 9. Acknowledgments - p. xix 10. Chapter One The hallmarks of cancer and immunology - p. 1 11. Chapter Two Innate and adaptive immunity in cancer - p. 19 12. Chapter Three Inflammation and cancer - p. 63 13. Chapter Four Novel immunotherapeutic approaches to cancer: Voltage-gated sodium channel expression in immune cells and tumors - p. 83 14. Chapter Five Immunoediting and cancer priming - p. 111 15. Chapter Six Metabolic reprogramming and immunity in cancer - p. 137 16. Chapter Seven Epigenetic programming of the immune responses in cancer - p. 197 17. Chapter Eight Cellular therapeutics in immuno-oncology - p. 237 18. Chapter Nine T-cell engaging bispecific antibody therapy - p. 267 19. Chapter Ten Role of microbiome in cancer immunotherapy - p. 321 20. Chapter Eleven STING pathway and modulation for cancer immunotherapy - p. 353 21. Chapter Twelve Oncolytic viruses in immunotherapy - p. 375 22. Chapter Thirteen Comparison of therapeutic strategies for immuno-oncology - p. 439 23. Chapter Fourteen Intrinsic and acquired cancer immunotherapy resistance - p. 463 24. Chapter Fifteen Preclinical and clinical toxicity of immuno-oncology therapies and mitigation strategies - p. 499 25. Index - p. 515
